Abstract: A buffered skin cream containing a linear polydimethylsiloxane polymer, a non-ionic emulsifier, aloe vera, mineral oil, sodium citrate, citric acid, a blend of propylene glycol, diazolidinyl urea, methyl paraben and propyl paraben, and water. The buffering capacity of the cream is provided through the incorporation of citric acid and sodium citrate in the composition. The buffering system results in the cream having a preferred pH in the range of about 4.5 to 6.0, and most preferably a pH of about 5.2 which neutralizes acidic and basic by-products of urine and fecal matter. The cream has a preferred viscosity in the range of 100,000-2,000,000 centipoise and a most preferred viscosity of about 250,000 to 1,000,000 centipoise. The cream is easily washed off with soap and water and is useful in the protection and treatment of diaper rash.

Abstract: The improved cleansing cream has a wrinkle-reducing effect when periodically applied to and rubbed into the human skin in wrinkled skin areas. The cream is non-irritating to the skin and includes a plurality of water-soluble granules which are of sufficient size, quantity and hardness to abrade the keratinized outer epidermal layer of the skin. The granules may be one or more inorganic salt, but preferably include one or more water-soluble vitamins and/or water-soluble vitamin-yielding salts, The cream also includes a base in which the granules are substantially uniformly disposed. The base preferably is in a major proportion with respect to the granules and is an oil and a petrolatum jelly. The water-soluble granules do not clog the pores of the skin but are absorbed into and nourish the skin.

Abstract: A process and composition for treating skin and hair that reduces the redistribution of sebum on the skin and hair of normal and seborrheic subjects and normalizes the redistribution of sebum on the skin and hair of asteatosic persons. The composition includes a polyfluoroether with perfluoroalkyl end groups in combination with at least one surfactant having an interface tension less than or equal to 15 dynes/cm with the polyfluoroether, at least one thickening agent, water and optionally a polyalcohol, foam booster, softener, dye, preservative, opacifier, or sequestering agent.

Abstract: The subject invention relates to compositions and methods for regulating wrinkles in mammalian skin by topical application of a 2-deoxy- or 2-deoxy-2-halo-lysophosphatidic acid compound having the structure: ##STR1## or a pharmaceutically acceptable salt thereof, wherein --R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 11 to about 23 carbon atoms; each --X-- is independently --0-- or --S--; --Y-- is --0-- or --CH.sub.2 --; and Z is --H or halo.

Abstract: High molecular weight petroleum fractions which have a low white oil content are admixed with a volatile siloxane, hexamethyldisiloxane, octamethylcyclotetrasiloxane and/or decamethylcyclopentasiloxane and a compound that is both hydrophobic and hydrophilic to provide an ointment base which enables these petrolatum fractions to be spread easily on the skin. Evaporation of the solvent leaves a high molecular weight petrolatum film on the skin that is nonirritating and yet highly resistant to mechanical removal.

Abstract: The present invention relates to composition and methods for enhancing and/or controlling epidermal, dermal and transdermal penetration of topically applied pharmacologically active agents by use of dibutyl adipate, or a mixture of dibutyl adipate and isopropyl myristate.

Abstract: The protein fraction from Leguminosae seeds, which is characterized by at least one band in polyacrylamide gel electrophoresis with sodium dodecyl sulfate, by relative molecular masses from 3,000 to 30,000 g/mole, by a content of total nitrogen of 14 to 20% and amino nitrogen of 1 to 2% related to the protein content and by further parameters defined in claim 1, is appropriate for the care of skin and for the treatment of inflammatory skin diseases, whereby the protein fraction is generally used as a concentrate of active substances or e.g. as a cream, lotion, emulsion, gel, face mask, powder or plaster.

Abstract: Acyl-Carnitine in pharmaceutical formulations provides therapeutic and preventive antiviral action against HSV, CMV, VZV, HIV and others.

Abstract: Bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. The invention also provides for a method of control releasing a pharmaceutical active comprising incorporating an active into the bioadhesive pharmaceutical carrier. The invention is particularly adaptable for oral use and teething gels.

Abstract: The invention relates to inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof and pharmaceutical compositions containing the same.The inclusion complex of 3-morpholino-sydnonimine or its salt formed with cyclodextrin derivative is prepared bya) reacting the 3-morpholino-sydnonimine or its salt in an aqueous medium with a cyclodextrin derivative and the complex is isolated from the solution by dehydratation, orb) high energy milling of 3-morpholino-sydnonimine or its salt and a cyclodextrin derivative.

Abstract: The invention relates to synthetic tetrapeptides that contain a peptide blocking group at the amino terminus and an enzyme inhibitor at the carboxy terminus, and their use in the prevention of schistosome parasite infection.

Abstract: Compositions containing 1.alpha.-hydroxyvitamin D homolog compounds in a suitable carrier and methods employing such compositions are disclosed for cosmetic uses in the treatment of various skin conditions such as lack of adequate skin firmness, wrinkles, dermal hydration and sebum secretion. Various formulations of the compositions including creams, lotions and ointments are disclosed for use topically, orally or parenterally in accordance with this invention.

Abstract: A new visualizing and anesthetic composition and the process for the preparation thereof. The composition, generally as a gel, contains an effective amount of a topical anesthetic, an effective amount of a visualizing agent and a pharmaceutically acceptable gelling reservoir as a heat exchanger and/or a light transmitter. The composition is useful for topical application to a region of mammalian skin to supply visualization to a lesion therein and to anesthetize the region for a subsequent destructive therapy.

Abstract: Disclosed are compositions useful for topical application to protect skin from ultraviolet radiation, which comprise effective amounts of the reaction product of a calcium compound such as calcium hydroxide, calcium oxide, or calcium carbonate, with citric acid, the reaction product exhibiting a calcium:citrate molar ratio of 2.50:2 to 2.95:2 and a 1% slurry of the reaction product in water at 25.degree. C. exhibiting a pH value of about 4 to below 7.

Abstract: A method for treating Candida infections of surfaces and cavities of dentures, the oral and vaginal cavities is disclosed. The method includes contacting an antifungal formulation onto the surface or cavity which is infected with the Candida fungus. The antifungal formulation includes a humectant in a concentration from about 20% to about 80%, lytic activating agents including inorganic monovalent anions and detergents. The antifungal formulation is contacted to the infected surface or cavity by suitable carrier or dispenser. The method is preferably directed towards the treatment of denture stomatitis in the oral cavity. The method preferably includes forming a replica of the denture surface using a suitable fungal growth medium to determine the location and, then, contacting the infected denture surface and surface of the oral cavity with the antifungal formulation.

Abstract: This invention relates to a method for administering systemically active agents, including therapeutic agents, through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent a non-toxic, effective, penetrating amount of a membrane penetration enhancer having the structural formula ##STR1## wherein X represents sulfur or two hydrogen atoms; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-18 and R is --CH.sub.3, ##STR2## wherein R" is H or halogen.

Abstract: Therapeutic as well as preventative measures to improve the cosmetic conditions or to alleviate the symptoms of dermatologic disorders with phenyl alpha acyloxyalkanoic acids and derivatives is disclosed. The cosmetic conditions and dermatologic disorders in humans in which the compounds may be useful include brittle or soft nails; abnormally thin skin, mucous membranes or wound; friction blisters; brittle hairs; pruritus; acne; and diseased nails, skin or mucous membranes due to natural or unnatural causes including but not limited to in flammations or infections. The phenyl alpha acyloxyalkanoic acids and derivatives include, for example, diphenyl alpha acetoxyacetic acid, phenyl alpha acetoxyacetic acid, phenyl alpha methyl alpha acetoxyacetic acid and phenyl alpha acetoxypropanoic acid. The compositions containing the active ingredients are also useful for treatment of skin, nails and hair conditions or disorders in domestic animals.

Abstract: This invention provides compositions comprising a physiologically-active agent and a compound having the structural formula ##STR1## wherein X may represent sulfur or two hydrogen atoms; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-18 and R is --CH.sub.3, ##STR2## wherein R" is H or halogen, in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal.

Abstract: Solubilized melanin based compositions supply melanin to skin, scalp and/or hair. The compositions consist of melanin, as an active ingredient, and a substance to solubilize the melanin blended together in a vehicle suitable for topical application. A melanin-based composition applied to the skin provides photoprotection of the human epidermis from exposure to ultraviolet rays. A melanin-based composition applied to wounds in the skin accelerates healing of the wounds. A melanin-based composition applied to the hair and scalp strengthens the hair.

Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

Abstract: This invention relates to a method for treating classical migraine headaches. Pursuant to this method, a therapeutic amount of .beta.-adrenergic-blocking agent is administered to a person suffering a migraine attack promptly upon onset of aura. The invention further relates to a method wherein the blocking agent is nasally administered.

Abstract: This invention relates to compositions/devices and methods for treating diseases of the oral cavity in humans and lower animals using polylactide/glycolide compositions/devices also containing triacetin for releasing drugs in the oral cavity.

Abstract: A skin moisturizing composition of lard leaf, natural mint, and virgin olive oil is produced by heating the lard leaf preferably to a temperature around 240.degree. F., adding the natural mint and heating preferably to about 360.degree. F., cooling the heated mixture and adding the virgin olive oil at a mixture temperature preferably about 120.degree. F.

Abstract: A continuous process for preparing a paste or cream like material which comprises the steps of means for forming under non vacuum conditions at a temperature of 90.degree. F. to 120.degree. F. a first low viscosity homogenous slurry of at least one non aqueous solvent and a gelling or bodying agent; means for forming a second low viscosity homogenous slurry under non vacuum conditions at a temperature of 90.degree. F. to 130.degree. F., means for forming a low viscosity mixture of said first low viscosity slurry and said second low viscosity slurry by a high shear mixing under non vacuum conditions at a temperature of 90.degree. F. to 130.degree. F. for 0.1 to 5 seconds; means for transforming under non vacuum and non mixing conditions at a temperature of 65.degree. F. to 120.degree. F., said low viscosity mixture into a non Newtonian mixture; and means for deaerating said non Newtonian mixture under vacuum conditions for a period of less than 3 seconds to form said paste or cream like material.

Abstract: A protective gel composition for coating skin surfaces, prior to covering skin with standard surgical gloves of other covers. The protective gel composition comprises controlled proportions in mixture by weight of the following components: (a) a water-insoluble base, (b) a water-repellent agent, (c) a water-insoluble surfactant and (d) a binder which binds together the components of the composition.

Abstract: The invention provides an analgesic cream containing ibuprofen with superior skin penetration properties obtained in part by maintaining a pH of 4 to 7.2 such that the ibuprofen is suspended in substantially solid crystalline form.

Abstract: This invention relates to the use of zinc salts as anti-viral agents in sexual lubricants. A zinc salt which releases divalent zinc ions in an aqueous carrier fluid is provided in a sexual lubricant formulation which is spread on the genitals before sexual intercourse. The mixture is non-irritating, and the zinc ions serve as an anti-viral agent to reduce the risk of contracting genital herpes if a sexual partner is infected. These lubricants may also reduce the risk of infection by other sexually transmitted viral diseases, such as hepatitis, papilloma viruses, and AIDS. A preferred lubricant formulation comprises water, a thickening or suspending agent, a lubricating agent, and a suitable zinc salt. Salts which have been tested and shown to be non-irritating during sexual intercourse include zinc acetate, zinc propionate, and zinc gluconate. Other zinc salts have also been identified which are soluble in water and have low pK values, which indicates a high rate of zinc ion release.

Abstract: An anti-inflammatory cosmetic composition having a large effect of absorbing and shielding all of UV-A, UV-B and UV-C, small degeneration with the passage of time even upon absorption of light, small influence upon the skin, not lowered effect of absorbing light and high stability for heat is provided. This anti-inflammatory cosmetic composition comprises 0.1 to 20% by weight of a hydroxyaryl-s-triazine compound represented by the following structural formula in a cosmetically acceptable oil carrier: ##STR1## wherein R.sub.1 and R.sub.2 represent, same or different, hydrogen atoms, chlorine atoms, hydroxyl groups, alkoxy groups of 1 to 18 carbon atoms, aryloxy groups of 6 to 8 carbon atoms or mono- or dialkylamino groups containing 1 to 4 carbon atoms and R.sub.3 and R.sub.4 represent, same or different, hydrogen atoms, chlorine atoms, alkyl groups of 1 to 8 carbon atoms, methoxy groups or ethoxy groups.

Abstract: A composition suitable for topical application to human skin comprises, in addition to a suitable vehicle an active ingredient which can control skin barrier functions. The active ingredient is (a) a long chain .omega.-hydroxy fatty acid or a carboxy-substituted derivative, (b) an hydroxy- or epoxy-derivative of an essential fatty acid or an ester formed between (a) and (b). Certain novel compounds of structures (a), (b) and (a)(b) esters are also claimed.

Abstract: Bioadhesive pharmaceutical carrier consisting essentially of a polymer blend of sodium carboxymethyl cellulose and xanthan gum or sodium alginate. The invention also provides for a method of control releasing a pharmaceutical active comprising incorporating an active into the bioadhesive pharmaceutical carrier. The invention is particularly adaptable for oral use and teething gels.

Abstract: A sebaceous excitosecretory agent comprising at least one of undecylenic acid, its salts, its esters, and its amide derivatives as an active ingredient. A process for exciting secretion of sebum comprising the step of applying onto a skin surface the above sebaceous excitosecretory agent. The sebaceous excitosecretory agent has a long-lasting action to excite secretion of sebum.

Abstract: The invention relates to novel transdermally applicable pharmaceutical preparations containing glycosides; a solvent selected from the group consisting of ethoxylated sterols and ethoxylated alcohols with 12 to 30 carbon atoms; and lipophilic ointment base.

Abstract: A topical emollient for the treatment of circulation induced lesions comprises a source of glucose and insulin. The topical emollient is utilized in a process wherein the emollient is applied to the affected surface for nourishment thereof and promotion of healing. The emollient also enhances the therapeutic benefits of other medicinal drugs which may be topically applied in conjunction with the insulin and glucose mixture.

Abstract: An excipient for a pharmaceutical compound which melts at body temperature but will not spontaneously deform at higher temperatures encountered in shipment and storage comprises:______________________________________ Low MW Polyethylene glycol 75-90% (M.P. about 37.degree. C.) Medium to high MW polyethylene glycol 0-4% Long chain saturated carboxylic acid 0-4% Polyethylene oxide 0-4% (MW 100,000-5,000,000) Colloidal silica 10-20%. ______________________________________The excipient is particularly advantageous for the preparation of dosage forms for buccal administration of pharmaceutical compounds.

Abstract: Methods of treating systemic viral infections are disclosed comprising the parenteral administration of pharmacologically effective amounts of ozonides of terpenes in pharmaceutically acceptable carriers. Methods for treating viral lesions are also disclosed. In particular, a method for treating retroviral infections is disclosed. More particularly, a method for treating HIV infections is disclosed. In addition, methods for treating infections of non-retroviral viruses are disclosed. Further, methods for treating T-cell deficiencies are also disclosed. Moreover, a method of producing blood for medical products which is free of viral activity is disclosed.

Abstract: An external analgesic lotion containing active ingredients of camphor and menthol to relieve pain in muscles, joints, or viscera distal at the site of application by stimulating cutaneous sensory receptors and a method of making such lotion and being made from camphor and menthol crystals.

Abstract: Antioxidant compositions and methods are disclosed that are prepared by the extraction of natural antioxidants from plant substrates.

Abstract: New polysaccharide esters are disclosed, and more precisely esters of acidic polysaccharides chosen from the group formed by carboxymethylcellulose, carboxymethyl starch and carboxymethylchitin. These new esters and some esters of the type already known are useful as medicaments, for the manufacture of pharmaceutical and cosmetic preparations, in the field of biodegradable plastic materials and, therefore, for the manufacture of medical, surgical and sanitary articles, as well as numerous other industrial sectors in the place of acidic polysaccharides now in common use.

Abstract: Pharmaecutical composition for topical use containing Defibrotide have been found effective in the therapy of local pathologies characterized by a reduced resistance of the blood capillary vessels.

Abstract: A therapeutic ointment having wet adherent properties and particularly well suited for delivery of medicaments to mucosal surfaces includes a base material comprising from about 3 to 15% by weight of a water soluble salt of a copolymer of methyl vinyl ether and maleic acid or anhydride in a polyethylene glycol ointment. Formulations of the base material with triamcinolone acetonide and lidocaine are particularly efficacious in the treatment of recurrent aphthous ulcers.

Abstract: Ointments are disclosed, which contain (a) 0.05-1 wt. % of deprodone propionate and (b) 89-99.95 wt. % of a base formed of white petroleum and a liquid hydrocarbon. The ointments may additional contain (c) 1-10 wt. % of a polyhydric alcohol.

Abstract: A method of treating a pruritic skin area in a mammal by application to the affected area of a gel composition containing from about 60 to about 90% ethyl alcohol, from about 0.5 to about 30% water, at least one gelling agent and a pharmaceutically effective amount of a topically active, antipruritic, antihistaminic agent. The gel may be applied to the affected area from one to five times daily.

Abstract: An ointment comprising an adenosine 3',5'-cyclic phosphate derivative as an active ingrediment, an ointment base having water-absorbing and drying properties, a saccharide and/or inorganic high polymer is disclosed. The ointment exhibits improved stability of the adenosine 3',5'-cyclic phosphate derivative.

Abstract: A skin protective sunscreen composition exhibiting enhanced water repellency and conditioning effects comprising ultraviolet blockers, aliphatic waxes and hydrophobic silicones disposed in a pharmacologically acceptable water-free carrier. The composition when used in accordance herewith is useful to protect mammals from solar radiation.

Abstract: A cyclic peptide designated FR115224, administered parenterally in a cyclodextrin carrier, which exhibits antiallergic activity.

Abstract: Topical polyethylene glycol based formulations for the delivery of 2-substituted-1-naphthols and indoles and particularly, 2-phenylmethyl-1-naphthol are provided. Said topical formulations exert excellent localized antiinflammatory activity while demonstrating low levels of skin penetration in vitro and in vivo thereby reducing unwanted side effects and reducing systemic toxicity associated with the active drug compounds.

Abstract: Medicated protective films are formed in situ on body tissue by applying a composition comprising (a) hydroxypropyl cellulose; (b) an esterification agent which reacts with the hydroxypropyl cellulose to form a reaction product which is soluble in the solvent of (c), but insoluble in body fluids at body temperatures; and (c) a nontoxic volatile solvent for said hydroxypropyl cellulose and said reaction products; and (d) a separate medicinal component. The films are tough, resilient and adhesive to body tissue including the mucosa.

Abstract: A barrier cream consisting essentially of at least one active ingredient chosen from the alkali metal salts of phenols, dispersed in a substantially anhydrous state in a base medium comprising a polyethylene glycol which has been at least partially etherified to reduce the free hydroxyl group content thereof. These creams are simple to prepare, effective for a reasonable period of time and do not produce adverse skin reaction, and are simple both to apply and to remove. They afford protection against chemical warfare agents of both the V and G types, and against mustard gas (H or HD).

Abstract: A protective system against chemical warfare agents consisting essentially of at least one alkali metal salt of phenol, acetone oxime, acetophenone oxime and 2,3-butanedione monoxime, a macrocycle chosen from 18-crown-6 or cryptand [2,2,2] and a solvent chosen from dioxolane, tetraglyme, dimethoxyethane, a polyethylene glycol or a polyethylene glycol mono- or diether the system also containing just enough water to dissolve the active ingredient. These systems afford protection against mustard gas (H or HD) and against chemical warfare agents of the V and G types.

Abstract: The monamine oxidase inhibitor drug L-deprenyl (phenylisopropyl methyl propynyl amine) is safely and conveniently used for the treatment of mental depression in a formulation applied to the skin of the patient. In this way the danger of side reaction due to the consumption of foods containing tyramine (the cheese effect) is minimized. Unlike other monamine oxidase drugs, such as Parnate, L-deprenyl does not cause skin irritation when used in this way.